Markets
Economy And Tourism In London
(Jakub Porzycki/Getty Images)

VF Corp. and Canada Goose climb higher on Baird upgrades as key fall shopping season kicks off

Analysts say a refreshed Vans playbook and buzzy Goose collections could fuel momentum during the back-to-school stretch.

Nia Warfield
8/26/25 10:59AM

Baird analysts are shopping for opportunities this season, upgrading VF Corp. and Canada Goose ahead of the crucial fall shopping stretch as brand refreshes, consumer buzz, and easing headwinds build optimism.

VF Corp.
Price target: $20, up from $14
Rating: “outperform” (from “neutral”)

VF Corp. shares jumped 5.6% after Baird upgraded the Vans and The North Face parent, betting the company is turning a corner. Analysts pointed to easing self-inflicted headwinds at Vans, which had been dragging results for several quarters. New product cycles, high-profile marketing moves (including an upcoming collection from singer SZA), and faster inventory resets could help the skate brand get back in step with younger shoppers.

At the same time, cost cutting and debt reduction are expected to shore up profitability, while The North Face remains a steady performer in outdoor wear. Tariffs are still a cloud, with VF estimating duties could slice roughly $40 million off fiscal 2025 profits, but Baird says the stock’s 50% drop from highs already reflects the risk and leaves more room for upside if the Vans reset pays off.

Canada Goose
Price target: CA$24, up from CA$18
Rating: “outperform” (from “neutral”)

Canada Goose shares climbed 5.9% after Baird also boosted its outlook for the outerwear company, citing a strong start to the year and signs of brand traction ahead of peak winter buying. Direct-to-consumer comps rose nearly 15% last quarter, powered by new spring and summer offerings, a hit Snow Goose capsule, and better in-store execution. Analysts also highlighted the brand’s expanding presence in China, where livestream shopping is giving it another leg up with luxury consumers.

Still, margins have been weighed down by heavy investment in marketing and brand refreshes. But Baird argues that with Goose still trading well below its 52-week highs, a combination of fresher product, improving seasonal leverage, and potential takeover interest will boost the company’s shares.

More Markets

See all Markets
markets

Robinhood, AppLovin, and Emcor pop on announcement of addition to S&P 500

Shares of Robinhood Markets, AppLovin, and Emcor are all rallying in post-market trading on Friday upon news that they’re being added to the S&P 500.

Shares of the brokerage popped 7.2%, the adtech company rose 7.8%, and the construction company was up a more modest 2.7% in the minutes following the announcement.

(Robinhood Markets, Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions.)

Strategy, another stock rumored to be in the running for inclusion in the benchmark US stock index that has been passed over, sank 2.5% in postmarket trading.

markets

Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism

Kenvue sank 15% Friday after a WSJ report said Health and Human Services Secretary Robert F. Kennedy Jr. may attempt to link prenatal Tylenol use to autism in an upcoming government report.

Kenvue, the maker of Tylenol and formerly a division of Johnson & Johnson prior to a 2023 spin-out, pushed back, saying the science shows “no causal link” between acetaminophen use during pregnancy and autism, and pointed to FDA and medical groups that agree on the drug’s safety.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

markets

Lucid surges following 6 days of losses after headlines misidentify Cantor Fitzgerald’s lower split-adjusted price target as a good thing

It’s been a shortened week, but still a rough one for Lucid. Investor blowback to the luxury EV maker’s 1-for-10 reverse stock split has sent shares to all time lows this week.

After six straight days of closing lower, Wall Street appears to have decided enough is enough and is loading up on Lucid shares on Friday, sending them up 13% in recent trading. As of 2:10pm eastern, Lucid trading volumes were at more than 240% of their 30 day average.

Some of the move could be attributed to traders reading headlines that don’t take into consideration Lucid’s reverse split. Cantor Fitzgerald on Friday slapped a new price target on Lucid of $20, compared to its previous target of $3. Some news outlets (not us!) presented that as an increase. The problem: With the 1-for-10 reverse split in effect, a comparable price target would have been $30. The new $20 target is actually... a cut.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.